Zymeworks (Zymeworks) Accumulated other comprehensive income (loss) : $-6.60 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Zymeworks's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $-6.60 Mil.

Zymeworks's quarterly Accumulated other comprehensive income (loss) declined from Jun. 2023 ($-7.81 Mil) to Sep. 2023 ($-8.30 Mil) but then increased from Sep. 2023 ($-8.30 Mil) to Dec. 2023 ($-6.60 Mil).

Zymeworks's annual Accumulated other comprehensive income (loss) stayed the same from Dec. 2021 ($-6.66 Mil) to Dec. 2022 ($-6.66 Mil) but then increased from Dec. 2022 ($-6.66 Mil) to Dec. 2023 ($-6.60 Mil).

Zymeworks Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Zymeworks's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Accumulated other comprehensive income (loss) Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-6.66

-6.60

Zymeworks Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-6.66	-5.94	-7.81	-8.30	-6.60

Zymeworks Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Zymeworks Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Zymeworks's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (Zymeworks) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

ZA8:Germany

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Executives

Paul Andrew Moore	officer: Chief Scientific Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle	officer: SVP & Chief Financial Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith	director, officer: Chair & CEO	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy	director	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael	director	108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas	officer: President & COO	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Troy Cox	director	C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton	director
Kelvin Neu	director	860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson	officer: Chief Medical Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4